EpiSign Inc. is pleased to highlight its involvement in a newly funded Ontario Genomics initiative, “Synthetic Reference Epigenomics: Building a Secure Cloud Framework for Scalable Rare Disease Diagnostics.”
The project focuses on developing secure, privacy-preserving infrastructure to enable large-scale epigenomic data analysis and collaboration. By leveraging synthetic reference datasets and cloud-based frameworks, the initiative aims to accelerate rare disease diagnosis while ensuring patient data remains protected.
Epigenomic testing – particularly DNA methylation profiling – has become an important tool for diagnosing rare genetic conditions, especially in cases unresolved by standard sequencing. EpiSign’s clinically validated, cloud-based platform supports this work by enabling laboratories worldwide to interpret methylation data using a growing database of disease-specific episignatures.
This initiative represents an important step toward more scalable, secure, and collaborative diagnostic workflows. EpiSign is proud to contribute to advancing the infrastructure needed to bring faster, more accurate rare disease diagnoses to patients globally.
Read more: